Abbas Suzanne J, Abed Fatimah S, Dhefer Iqbal H
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kerbala, Kerbala, Iraq.
Department of Basic sciences, College of Dentistry, University of Kerbala, Iraq.
J Taibah Univ Med Sci. 2021 Aug 18;17(1):45-50. doi: 10.1016/j.jtumed.2021.07.010. eCollection 2022 Feb.
Obesity is a serious global issue with a massive impact on the health and life of people worldwide. Besides being a neuropeptide, kisspeptin is an important adipokine involved in regulating energy homeostasis and body weight. This study aims to clarify the underlying role of kisspeptin in obesity.
This case-control study included 110 obese individuals with BMI of 33.45 ± 0.36 kg/m and 84 normal-weight individuals with BMI 21.35 ± 0.24 kg/m. The individuals' ages ranged from 21 to 45 years (31.56 ± 0.67 year). Kisspeptin, neutrophil epithelial activating peptide (ENA-78), and ghrelin were determined using the enzyme-linked immunosorbent assay (ELISA) technique. Lipid profile parameters were determined using the commercial colorimetric techniques.
Plasma concentrations of kisspeptin and ENA-78 were significantly higher in obese subjects (kisspeptine of obese: 437.66 ± 34.96 pg/ml; kisspeptine of normal-weight: 250.10 ± 16.16 pg/ml, < 0.0001; ENA-78 of obese: 144.80 ± 23.94 pg/ml; ENA-78 of normal-weight: 50.97 ± 3.91 pg/ml, < 0.001). Ghrelin concentrations showed no significant difference between obese and normal-weight subjects. The lipid profile parameters significantly differed between obese and normal-weight subjects.
Kisspeptin is associated with obesity. An increased mass of adipose tissue could be responsible not only for increased kisspeptin secretion but also for the increased ENA-78 secretion. Kisspeptin may act as an adipokine more than a neuropeptide in obese population. Further studies on humans are required to establish the underlying role of kisspeptin in adipocyte differentiation and lipogenesis.
肥胖是一个严重的全球性问题，对全世界人们的健康和生活有着巨大影响。除了作为一种神经肽， kisspeptin还是一种重要的脂肪因子，参与调节能量平衡和体重。本研究旨在阐明kisspeptin在肥胖中的潜在作用。
本病例对照研究纳入了110名肥胖个体，其体重指数（BMI）为33.45±0.36kg/m²，以及84名体重正常个体，其BMI为21.35±0.24kg/m²。个体年龄在21至45岁之间（31.56±0.67岁）。使用酶联免疫吸附测定（ELISA）技术测定kisspeptin、中性粒细胞上皮激活肽（ENA-78）和胃饥饿素。使用商业比色技术测定血脂谱参数。
肥胖受试者血浆中kisspeptin和ENA-78的浓度显著更高（肥胖者的kisspeptin：437.66±34.96pg/ml；体重正常者的kisspeptin：250.10±16.16pg/ml，P<0.0001；肥胖者的ENA-78：144.80±23.94pg/ml；体重正常者的ENA-78：50.97±3.91pg/ml，P<0.001）。胃饥饿素浓度在肥胖和体重正常受试者之间无显著差异。肥胖和体重正常受试者之间的血脂谱参数有显著差异。
Kisspeptin与肥胖有关。脂肪组织量增加不仅可能导致kisspeptin分泌增加，还可能导致ENA-78分泌增加。在肥胖人群中，kisspeptin可能更多地作为一种脂肪因子而非神经肽发挥作用。需要对人类进行进一步研究，以确定kisspeptin在脂肪细胞分化和脂肪生成中的潜在作用。
